Ingrid Arijs

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6900334/publications.pdf

Version: 2024-02-01



ΙΝΟΡΙΟ ΔΡΙΙς

#	Article	IF	CITATIONS
1	The Dynamics of Nucleotide Variants in the Progression from Low–Intermediate Myeloma Precursor Conditions to Multiple Myeloma: Studying Serial Samples with a Targeted Sequencing Approach. Cancers, 2022, 14, 1035.	1.7	0
2	Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. Nature Communications, 2021, 12, 1861.	5.8	68
3	A randomized trial regarding antimicrobial prophylaxis (AMP) in transurethral resection of bladder tumor (TURB). World Journal of Urology, 2021, 39, 3839-3844.	1.2	2
4	A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nature Medicine, 2021, 27, 820-832.	15.2	330
5	Current Methodological Challenges of Single-Cell and Single-Nucleus RNA-Sequencing in Glomerular Diseases. Journal of the American Society of Nephrology: JASN, 2021, 32, 1838-1852.	3.0	21
6	Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity. Nature Communications, 2021, 12, 4117.	5.8	170
7	P-058: The dynamics of nucleotide variants in the progression from myeloma precursor conditions to multiple myeloma using targeted sequencing of serial bone marrow samples. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S70.	0.2	0
8	Transcriptional Changes in Kidney Allografts with Histology of Antibody-Mediated Rejection without Anti-HLA Donor-Specific Antibodies. Journal of the American Society of Nephrology: JASN, 2020, 31, 2168-2183.	3.0	60
9	Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models. Stem Cell Reports, 2020, 14, 717-729.	2.3	105
10	Antibiotic prophylaxis in TURP: a prospective analysis concerning antibiotic stewardship and a potential reduction of antibiotic use in TURP. World Journal of Urology, 2019, 37, 2467-2472.	1.2	5
11	Fungal Bezoars Mimicking an Enterovesica Fistula: A Unique Case Report. Current Urology, 2019, 13, 107-109.	0.4	0
12	Gene and Mirna Regulatory Networks During Different Stages of Crohn's Disease. Journal of Crohn's and Colitis, 2019, 13, 916-930.	0.6	41
13	Difference in Pathomechanism Between Crohn's Disease and Ulcerative Colitis Revealed by Colon Transcriptome. Inflammatory Bowel Diseases, 2019, 25, 722-731.	0.9	22
14	Archival May-Grünwald–Giemsa-Stained Bone Marrow Smears Are an Eligible Source for Molecular DNA Research. Biopreservation and Biobanking, 2019, 17, 274-281.	0.5	2
15	Selective Suprascapular and Axillary Nerve Block Versus Interscalene Plexus Block for Pain Control After Arthroscopic Shoulder Surgery. Regional Anesthesia and Pain Medicine, 2018, 43, 1.	1.1	43
16	Prognostic Biomarkers in the Progression From MGUS to Multiple Myeloma: A Systematic Review. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 235-248.	0.2	11
17	Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC. Gut, 2018, 67, 43-52.	6.1	137
18	Biopsy-derived Intestinal Epithelial Cell Cultures for Pathway-based Stratification of Patients With Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2018, 12, 178-187.	0.6	13

INGRID ARIJS

#	Article	IF	CITATIONS
19	Specific members of the predominant gut microbiota predict pouchitis following colectomy and IPAA in UC. Gut, 2017, 66, 79-88.	6.1	114
20	RISK stratification in paediatric Crohn's disease. Lancet, The, 2017, 389, 1672-1674.	6.3	3
21	Inhibition of gelatinase B/MMP-9 does not attenuate colitis in murine models of inflammatory bowel disease. Nature Communications, 2017, 8, 15384.	5.8	40
22	Neurological outcome after minimal invasive coronary artery surgery (NOMICS): protocol for an observational prospective cohort study. BMJ Open, 2017, 7, e017823.	0.8	4
23	Genetic and Transcriptomic Bases of Intestinal Epithelial Barrier Dysfunction in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2017, 23, 1718-1729.	0.9	156
24	Review Article. Absent in melanoma 2 (AIM2) in the intestine: diverging actions with converging consequences. Inflammasome, 2017, 3, 1-9.	0.6	2
25	Submucosal Plexitis as a Predictive Factor for Postoperative Endoscopic Recurrence in Patients with Crohn's Disease Undergoing a Resection with lleocolonic Anastomosis: Results from a Prospective Single-centre Study. Journal of Crohn's and Colitis, 2017, 11, 212-220.	0.6	42
26	P035 TNF-driven pathways are increased at baseline in Crohn's disease patients not responding to infliximab. Journal of Crohn's and Colitis, 2017, 11, S96-S97.	0.6	0
27	Genome-Wide Copy Number Variation Scan Identifies Complement Component C4 as Novel Susceptibility Gene for Crohn's Disease. Inflammatory Bowel Diseases, 2016, 22, 505-515.	0.9	12
28	The molecular biology of matrix metalloproteinases and tissue inhibitors of metalloproteinases in inflammatory bowel diseases. Critical Reviews in Biochemistry and Molecular Biology, 2016, 51, 295-358.	2.3	62
29	Genetic Deletion of Tissue Inhibitor of Metalloproteinase-1/TIMP-1 Alters Inflammation and Attenuates Fibrosis in Dextran Sodium Sulphate-induced Murine Models of Colitis. Journal of Crohn's and Colitis, 2016, 10, 1336-1350.	0.6	34
30	Strong Upregulation of AIM2 and IFI16 Inflammasomes in the Mucosa of Patients with Active Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 2673-2682.	0.9	94
31	Indications for distinct pathogenic mechanisms of asbestos and silica through gene expression profiling of the response of lung epithelial cells. Human Molecular Genetics, 2015, 24, 1374-1389.	1.4	19
32	Serum Neutrophil Gelatinase B-associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Marker for Mucosal Healing in Patients with Crohn's Disease. Journal of Crohn's and Colitis, 2015, 9, 1079-1087.	0.6	39
33	Inflammationâ€Induced Downregulation of Butyrate Uptake and Oxidation Is Not Caused by a Reduced Gene Expression. Journal of Cellular Physiology, 2015, 230, 418-426.	2.0	9
34	Faecal metabolite profiling identifies medium-chain fatty acids as discriminating compounds in IBD. Gut, 2015, 64, 447-458.	6.1	185
35	Prolactin Receptors and Placental Lactogen Drive Male Mouse Pancreatic Islets to Pregnancy-Related mRNA Changes. PLoS ONE, 2015, 10, e0121868.	1.1	39
36	Neutrophil Gelatinase B–associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Serum Marker of Mucosal Healing in Ulcerative Colitis. Inflammatory Bowel Diseases, 2014, 20, 1198-1207.	0.9	47

Ingrid Arijs

#	Article	IF	CITATIONS
37	Infliximab Restores the Dysfunctional Matrix Remodeling Protein and Growth Factor Gene Expression in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2014, 20, 339-352.	0.9	36
38	Genetic and microbial factors modulating the ubiquitin proteasome system in inflammatory bowel disease. Gut, 2014, 63, 1265-1274.	6.1	72
39	A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis. Gut, 2014, 63, 1275-1283.	6.1	1,353
40	Integrated miRNA and mRNA Expression Profiling in Inflamed Colon of Patients with Ulcerative Colitis. PLoS ONE, 2014, 9, e116117.	1.1	73
41	Impaired Expression of Genes Involved in the Butyrate Oxidation Pathway in Crohn's Disease Patients. Inflammatory Bowel Diseases, 2013, 19, E43-E44.	0.9	10
42	<scp>I</scp> nterleukinâ€15 receptor α expression in inflammatory bowel disease patients before and after normalization of inflammation with infliximab. Immunology, 2013, 138, 47-56.	2.0	13
43	Genetic association and functional role of Crohn disease risk alleles involved in microbial sensing, autophagy, and endoplasmic reticulum (ER) stress. Autophagy, 2013, 9, 2046-2055.	4.3	54
44	Correlation Between the Endoscopic and Histologic Score in Assessing the Activity of Ulcerative Colitis. Inflammatory Bowel Diseases, 2013, 19, 1194-1201.	0.9	111
45	Decreased Mucosal Sulfide Detoxification Capacity in Patients With Crohn's Disease. Inflammatory Bowel Diseases, 2013, 19, E70-E72.	0.9	16
46	Unique Gene Expression and MR T2 Relaxometry Patterns Define Chronic Murine Dextran Sodium Sulphate Colitis as a Model for Connective Tissue Changes in Human Crohn's Disease. PLoS ONE, 2013, 8, e68876.	1.1	42
47	Intestinal expression of SHIP in inflammatory bowel diseases. Gut, 2012, 61, 956-957.	6.1	14
48	P459 Predominant dysbiosis in patients with ulcerative colitis is different from Crohn's disease patients. Journal of Crohn's and Colitis, 2012, 6, S192.	0.6	1
49	Impaired butyrate oxidation in ulcerative colitis is due to decreased butyrate uptake and a defect in the oxidation pathway*. Inflammatory Bowel Diseases, 2012, 18, 1127-1136.	0.9	91
50	Genes Associated with Intestinal Permeability in Ulcerative Colitis: Changes in Expression Following Infliximab Therapy. Inflammatory Bowel Diseases, 2012, 18, 1399-1410.	0.9	39
51	Decreased mucosal sulfide detoxification is related to an impaired butyrate oxidation in ulcerative colitis. Inflammatory Bowel Diseases, 2012, 18, 2371-2380.	0.9	39
52	Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro. Inflammatory Bowel Diseases, 2012, 18, 401-408.	0.9	150
53	Mucosal Gene Expression of Cell Adhesion Molecules, Chemokines, and Chemokine Receptors in Patients With Inflammatory Bowel Disease Before and After Infliximab Treatment. American Journal of Gastroenterology, 2011, 106, 748-761.	0.2	121
54	Seroreactivity against glycolytic enzymes in inflammatory bowel disease. Inflammatory Bowel Diseases, 2011, 17, 557-564.	0.9	24

Ingrid Arijs

#	ARTICLE	IF	CITATIONS
55	Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximabâ€. Inflammatory Bowel Diseases, 2010, 16, 1299-1310.	0.9	90
56	Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease‡. Inflammatory Bowel Diseases, 2010, 16, 2090-2098.	0.9	151
57	Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium. Vaccine, 2010, 28, 7507-7513.	1.7	206
58	Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut, 2009, 58, 492-500.	6.1	479
59	Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflammatory Bowel Diseases, 2009, 15, 1295-1301.	0.9	584
60	Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut, 2009, 58, 1612-1619.	6.1	346
61	Mucosal Gene Expression of Antimicrobial Peptides in Inflammatory Bowel Disease Before and After First Infliximab Treatment. PLoS ONE, 2009, 4, e7984.	1.1	237
62	W1206 Impaired Sulphide Detoxification in Ulcerative Colitis Is Related to Inflammation. Gastroenterology, 2008, 134, A-654-A-655.	0.6	0
63	Full Genome-Based Classification of Rotaviruses Reveals a Common Origin between Human Wa-Like and Porcine Rotavirus Strains and Human DS-1-Like and Bovine Rotavirus Strains. Journal of Virology, 2008, 82, 3204-3219.	1.5	791
64	Anti–α-enolase Antibodies in Patients with Inflammatory Bowel Disease. Clinical Chemistry, 2008, 54, 534-541.	1.5	41
65	Evolutionary History and Global Spread of the Emerging G12 Human Rotaviruses. Journal of Virology, 2007, 81, 2382-2390.	1.5	276
66	Predictors of early response to infliximab in patients with ulcerative colitis. Inflammatory Bowel Diseases, 2007, 13, 123-128.	0.9	166
67	G8 Rotavirus Strains Isolated in the Democratic Republic of Congo Belong to the DS-1-Like Genogroup. Journal of Clinical Microbiology, 2006, 44, 1801-1809.	1.8	109